This article breaks down the key changes in plain language, what they mean for current patients, and what your next steps should be.
What Is GLP-1 Compounding and Why Has It Been So Common?
GLP-1 receptor agonists like semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound) have become some of the most prescribed medications in the United States for weight management and type 2 diabetes.
However, branded versions can cost well over $1,000 per month without insurance. When both drugs were placed on the FDA’s official drug shortage list starting in 2022, licensed compounding pharmacies were legally permitted to prepare compounded versions. These compounded alternatives were available at roughly $150 to $300 per month, making treatment far more accessible for millions of patients.
That shortage-driven flexibility created the widespread market for compounded GLP-1 medications that many patients rely on today.
What the FDA Changed in 2026
The Shortage Status Has Ended
The FDA declared the semaglutide shortage resolved in early 2025. Enforcement grace periods followed:
- For 503A state-licensed pharmacies, the period of enforcement discretion ended April 22, 2025
- For 503B outsourcing facilities, it ended May 22, 2025
Once a drug is removed from the shortage list, the legal basis for most large-scale compounding of that drug disappears.
The April 2026 Proposal
On April 30, 2026, the FDA took an even more definitive step. The agency formally proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List entirely. The FDA’s reasoning was direct: now that FDA-approved versions of these drugs are commercially available, there is no clinical need for outsourcing facilities to compound them from bulk drug substances.
In the same period, the FDA sent 30 warning letters to telehealth companies in March 2026 alone, signaling strong enforcement intent across the board.
The public comment period for this proposal closed on July 30, 2026. As of now, the FDA is reviewing those comments before issuing a final rule. The direction, however, is clear.
Safety Concerns Behind the Crackdown
The FDA’s move is not purely procedural. By May 2026, the agency had recorded over 990 adverse event reports linked to compounded semaglutide and more than 730 reports tied to compounded tirzepatide. Many cases involved dosing errors from patients self-administering from multi-dose vials, some of which required hospitalisation.
The FDA has also flagged concerns about counterfeit products and mislabeled compounded medications circulating through online channels. A study from March 2026 even identified a previously unknown chemical compound in mass-compounded tirzepatide mixed with vitamin B12, the long-term safety of which is still unknown.
These are serious patient safety concerns, not just regulatory technicalities.
What This Means for Patients Currently on Compounded GLP-1s
Nothing Changes Overnight
If you are currently receiving compounded semaglutide or compounded tirzepatide through a licensed pharmacy, your treatment does not end immediately. The final FDA rule has not yet been published, and compounding under documented individual medical necessity may still be permissible in specific circumstances.
However, the window for large-scale, routine compounding of these medications is clearly closing.
503A Compounding May Still Apply in Some Cases
Section 503A of the federal law governs smaller, state-licensed compounding pharmacies that prepare medications for individual patients with a valid prescription. Compounding under this pathway remains an option when a patient’s specific medical need genuinely cannot be met by an FDA-approved commercial product.
This is where working with a reputable, clinically guided compounding pharmacy in Sugar Land, TX matters most. The standard is no longer “the brand is expensive.” The standard is documented, individualised medical necessity.
The “Add Vitamins and Call It Different” Approach Is Over
Some compounders attempted to classify their products as distinct formulations by adding B vitamins, amino acids, or other additives, hoping this would exempt them from FDA restrictions. As of late 2025, over 80% of compounded weight loss medications contained such additions.
The FDA has explicitly rejected this approach. Adding extras does not make a compounded GLP-1 a meaningfully different product. Patients should be cautious of any provider making that argument.
What Patients Should Do Right Now
Given the evolving FDA GLP-1 regulations, patients currently on or considering compounded GLP-1 therapy should take these steps:
- Talk to your prescriber. Ask whether your current compounded medication still complies with 2026 regulations and whether your prescription is supported by documented individual medical necessity.
- Verify your pharmacy’s credentials. Ensure your compounding pharmacy is properly licensed under 503A or 503B and follows current Good Manufacturing Practice standards. Learn more about how The Chemist Pharmacy compounds medications.
- Explore your options for branded medications. In some cases, manufacturer savings programs, insurance coverage, or patient assistance programs may make branded GLP-1 medications more affordable than they initially appear. Our weight loss services outlines the clinically guided options we support.
- Stay away from unregulated online sources. The FDA has specifically flagged counterfeit compounded GLP-1 products sold online as a patient safety risk.
- Consider supporting therapies. Patients transitioning off compounded GLP-1s may benefit from complementary support such as peptide therapy for metabolic health, or hormone therapy if hormonal imbalance is contributing to weight challenges. A consultation can help you determine what is right for your situation.
Frequently Asked Questions
Q: Is compounded semaglutide still legal in 2026?
Large-scale bulk compounding of semaglutide by 503B outsourcing facilities is facing a proposed ban. However, 503A compounding pharmacies may still prepare compounded semaglutide for individual patients with a valid prescription and documented medical necessity, provided they follow current FDA guidelines. The final rule has not been issued yet.
Q: Can I still get compounded tirzepatide from my pharmacy?
The same rules apply to compounded tirzepatide. The FDA’s April 2026 proposal targets 503B outsourcing facilities. Whether your specific situation qualifies under 503A individual compounding depends on your prescriber’s clinical documentation and your pharmacy’s compliance status.
Q: Why is the FDA doing this now?
The FDA acted because the drug shortage that originally justified widespread GLP-1 compounding has ended. Additionally, growing adverse event reports and safety concerns about unregulated compounded products have pushed the agency to enforce stricter oversight.
Q: What happens if the final rule is published?
Once the final rule is issued, 503B outsourcing facilities will be prohibited from compounding semaglutide, tirzepatide, and liraglutide from bulk substances. 503A pathways with proper documentation may still exist for individual patients, but this should be confirmed with your prescriber and pharmacy.
Q: Should I stop my GLP-1 treatment immediately?
No. Do not stop any prescribed medication without speaking to your healthcare provider first. The regulatory changes affect access and sourcing, not the clinical appropriateness of your treatment. Work with your provider to find a compliant path forward.
